Literature DB >> 8971286

Time to maximum effect of lansoprazole on gastric pH in normal male volunteers.

N J Bell1, R H Hunt.   

Abstract

BACKGROUND: The time to maximum inhibition of gastric acidity resulting from repeated oral dosing with lansoprazole 30 mg daily for 7 days was studied in nine healthy male volunteers.
METHODS: Twenty-four hour intragastric pH monitoring was performed before treatment and on days 1, 3, 5 and 7 of dosing with lansoprazole. Blood samples were taken for the estimation of plasma lansoprazole concentrations.
RESULTS: Lansoprazole 30 mg increased mean 24-h intragastric pH to 3.57 on day 1 compared with baseline mean pH of 2.11 (P < 0.05). The mean intragastric pH during the morning period (08.00-13.00 h) was significantly higher on days 3, 5 and 7 than on day 1, but no consistent differences between day 1, 3, 5 and 7 were noted for subsequent periods (13.00-18.00, 18.00-21.00 and 23.00-07.00 h). There were no differences in mean pH between days 3, 5 and 7. Intragastric pH was maintained above pH 3 for 54.7, 60.1, 61.9 and 67.4% of the time on days 1, 3, 5 and 7, respectively. Lansoprazole pharmacokinetic parameters did not change with daily dosing. The area under the lansoprazole plasma concentration-time curve correlated with the intragastric pH (P < 0.005).
CONCLUSIONS: Lansoprazole 30 mg raised intragastric pH significantly from baseline on day 1 to a maximum effect as early as 6 h after the first dose. The degree and duration of acid suppression confirm the usefulness of lansoprazole for the treatment of acid-related disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971286     DOI: 10.1046/j.1365-2036.1996.103242000.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects.

Authors:  Narayana I Narasimhan; David J Dorer; Jeffrey Davis; Christopher D Turner; Daryl Sonnichsen
Journal:  Clin Drug Investig       Date:  2014-10       Impact factor: 2.859

2.  A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.

Authors:  Richat Abbas; Cathie Leister; Daryl Sonnichsen
Journal:  Clin Drug Investig       Date:  2013-08       Impact factor: 2.859

3.  Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers.

Authors:  Keith G Tolman; Jörg Täubel; Steven Warrington; Yi-Lin Chiu; Betsy L Pilmer; Wei-Jian Pan
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

4.  Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects.

Authors:  Kiana Keyvanjah; Daniel DiPrimeo; Ai Li; Mohammad Obaidi; Dennis Swearingen; Alvin Wong
Journal:  Br J Clin Pharmacol       Date:  2016-10-16       Impact factor: 4.335

5.  Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates.

Authors:  Seung Bae Yoon; Jae Myung Park; Jong-Yul Lee; Myong Ki Baeg; Chul-Hyun Lim; Jin Soo Kim; Yu Kyung Cho; In Seok Lee; Sang Woo Kim; Myung-Gyu Choi
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

Review 6.  pH, healing rate, and symptom relief in patients with GERD.

Authors:  J Q Huang; R H Hunt
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun

7.  Effect of Acid Suppressants on Non-Helicobacter pylori Helicobacters Within Parietal Cells.

Authors:  Masahiko Nakamura; Futa Murasato; Anders Øverby; Yosuke Kodama; Hirofumi Michimae; Kazuki Sasaki; Bram Flahou; Freddy Haesebrouck; Somay Y Murayama; Shinichi Takahashi; Masayuki Uchida; Hidekazu Suzuki; Hidenori Matsui
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

8.  The Impact of Gastric Juice pH on the Intraluminal Therapy for Helicobacter pylori Infection.

Authors:  Yu-Chio Wang; Yen-Po Chen; Cheng-Yu Ho; Ting-Wen Liu; Cheng-Hsin Chu; Horng-Yuan Wang; Tai-Cherng Liou
Journal:  J Clin Med       Date:  2020-06-14       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.